If ‘atypical’ neuroleptics did not exist, it wouldn’t be necessary to invent them: Perverse incentives in drug development, research, marketing and clinical practice
To access this article, please choose from the options below
PII: S0306-9877(05)00414-7
doi:10.1016/j.mehy.2005.08.013
© 2005 Elsevier Ltd. All rights reserved.
